Cognitive Impairment Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Cognitive Impairment Clinical Trials Market Report Overview
In total there were 1,537 clinical trials conducted on cognitive impairment, as of February 2023, of which the majority of them were conducted in Asia-Pacific. The cognitive impairment clinical trial market research report provides an overview of the clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Cognitive Impairment Clinical Trials Market Segmentation by Regions and Countries
The key regions analyzed for the cognitive impairment clinical trials market are North America, Asia-Pacific, Middle East & Africa, Europe, and South & Central America. The Asia-Pacific region dominates the market, followed by North America, and Europe respectively. China accounted for the highest number of cognitive impairment clinical trials in the Asia-Pacific region, followed by Australia.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, there were 1,045 clinical trials conducted on cognitive impairment, as of February 2023 in G7 Countries, of which the majority of clinical trials were conducted in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, China has the highest proportion of the clinical trials on cognitive impairment. There were 394 clinical trials conducted on cognitive impairment, as of February 2023 in E7 Countries, of which the majority of the clinical trials were conducted in China.
Cognitive Impairment Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the cognitive impairment clinical trials market, download a free report sample
Cognitive Impairment Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the cognitive impairment clinical trials market are institution, company, and the government. Out of them, the institution sponsor type accounted for the largest cognitive impairment clinical trials market share as of February 2023.
Cognitive Impairment Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the cognitive impairment clinical trials market, download a free report sample
Cognitive Impairment Clinical Trials Market - Competitive Landscape
Some of the leading sponsors in the cognitive impairment clinical trials market are C. H. Boehringer Sohn AG & Co KG, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Eli Lilly and Co, Biogen Inc, AbbVie Inc, Novartis AG, Eisai Co Ltd, Merck & Co Inc, and Collaborative Neuroscience Network LLC. C. H. Boehringer Sohn AG & Co KG has conducted the highest number of cognitive impairment clinical trials as of February 2023, and is followed by Takeda Pharmaceutical Co Ltd and Pfizer Inc.
Cognitive Impairment Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading sponsors in the cognitive impairment clinical trials market, download a free report sample
Cognitive Impairment Clinical Trials Market Research Overview
Key Regions | Europe, North America, Asia-Pacific, the Middle East & Africa, and South & Central America |
Key Countries (G7) | United States, United Kingdom, Germany, France, Italy, Canada, and Japan |
Key Countries (E7) | Brazil, Russia, India, China, Mexico, Turkey, and Indonesia |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | C. H. Boehringer Sohn AG & Co KG, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Eli Lilly and Co, Biogen Inc, AbbVie Inc, Novartis AG, Eisai Co Ltd, Merck & Co Inc, and Collaborative Neuroscience Network LLC |
Segments Covered in the Report
Cognitive Impairment Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Cognitive Impairment Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies about investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Takeda Pharmaceutical Co Ltd
Pfizer Inc
Eli Lilly and Co
Biogen Inc
AbbVie Inc
Novartis AG
Eisai Co Ltd
Merck & Co Inc
Collaborative Neuroscience Network LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What is the total number of cognitive impairment clinical trials conducted till 2023?
In total there were 1,537 clinical trials conducted on cognitive impairment, as of February 2023.
-
Which are the key regions in the cognitive impairment clinical trials market?
The key regions in the cognitive impairment clinical trials market are Europe, North America, Asia-Pacific, the Middle East & Africa, and South & Central America.
-
What are the key sponsor types in the cognitive impairment clinical trials market?
The key sponsor types in the cognitive impairment clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the cognitive impairment clinical trials market?
Some of the leading sponsors in the cognitive impairment clinical trials market are C. H. Boehringer Sohn AG & Co KG, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Eli Lilly and Co, Biogen Inc, AbbVie Inc, Novartis AG, Eisai Co Ltd, Merck & Co Inc, and Collaborative Neuroscience Network LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.